Explore

Rapid Read Rapid Read
Rare Heart Disease Diagnosis in Sisters Highlights Genetic Health Challenges

Rare Heart Disease Diagnosis in Sisters Highlights Genetic Health Challenges

Megan Kaverman, diagnosed with heritable pulmonary arterial hypertension at 27, discovered her sister, Katie Gusching, exhibited similar symptoms two years later. This rare genetic disorder, affecting less than 4% of cases, causes the small arteries in the lungs to narrow, leading to increased blood pressure and potential heart failure. Both sisters receive treatment at the Cleveland Clinic and participate in clinical trials for new therapies. Their story emphasizes the challenges of diagnosing rare diseases and the importance of genetic awareness in family health.
Rapid Read Rapid Read
Rare Heart Disease Diagnosis Leads to Family Discovery and Advocacy

Rare Heart Disease Diagnosis Leads to Family Discovery and Advocacy

Megan Kaverman was diagnosed with heritable pulmonary arterial hypertension, a rare genetic disorder, at the age of 27 after experiencing severe fatigue and breathing difficulties. Her condition was initially dismissed by doctors due to her young age. The disease causes the small arteries in the lungs to narrow, increasing blood pressure and straining the heart. Kaverman's diagnosis led to her sister, Katie Gusching, discovering she had the same condition after experiencing similar symptoms. Both sisters are now receiving treatment at the Cleveland Clinic and participating in clinical trials to explore new care options. They are also advocating for awareness of the disease, which affects fewer than one in a million people.
Rapid Read Rapid Read
Toddler's Rare Genetic Disorder Reveals Family's Genetic Risk

Toddler's Rare Genetic Disorder Reveals Family's Genetic Risk

Samantha Clark, an occupational therapist from Malta, New York, has shared the story of her 17-month-old daughter, Poppy, who appears healthy but is living with Ataxia-Telangiectasia (A-T). This rare genetic disorder affects balance, coordination, the immune system, and increases cancer risk. Despite appearing healthy, Poppy requires weekly antibody infusions as her body cannot produce enough antibodies. The condition has begun affecting her mobility, and doctors have warned of increased risks of chronic lung disease, lymphoma, and leukemia. The diagnosis was confirmed after extensive testing revealed Poppy was missing CD19 cells, leading to a genetic panel screening that identified the disorder. Both Clark and her husband, Kyle Parkinson, discovered they carry the ataxia-telangiectasia mutated (ATM) gene, which Poppy inherited.
Rapid Read Rapid Read
Deramiocel DMD Phase III Trial Shows Promise in Slowing Disease Progression

Deramiocel DMD Phase III Trial Shows Promise in Slowing Disease Progression

The Phase III trial of deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD), has shown promising results in slowing disease progression. Conducted across 20 outpatient sites in the U.S., the trial involved 106 male participants aged 10 to 22 with advanced DMD. The treatment, consisting of human allogeneic cardiosphere-derived cells, was administered intravenously every three months. Results indicated a significant reduction in the decline of upper limb function and improvements in cardiac function, addressing major causes of illness and premature death in DMD patients. This trial marks the first Phase III trial of a donor cell-based therapy administered through the bloodstream for a genetic disease.
Rapid Read Rapid Read
Cleveland Clinic Launches Drone Prescription Delivery in Beachwood

Cleveland Clinic Launches Drone Prescription Delivery in Beachwood

The city of Beachwood, Ohio, has announced a new initiative to deliver prescriptions via drones, operated by the Cleveland Clinic in collaboration with Zipline. This program aims to enhance the delivery of medical prescriptions directly to patients' homes, operating during regular business hours from Monday to Friday. The announcement, made through a Facebook post, has sparked mixed reactions among residents. While some are excited about the technological advancement, others have logistical concerns about the delivery process. The city plans to provide more details about the program in early August.
Trendline Trendline
Novo Nordisk's IL-6 Inhibitor Ziltivekimab Fails in Cardiovascular Phase 3 Trial, Shares Drop

Novo Nordisk's IL-6 Inhibitor Ziltivekimab Fails in Cardiovascular Phase 3 Trial, Shares Drop

Novo Nordisk's IL-6 Inhibitor Ziltivekimab Fails in Cardiovascular Phase 3 Trial, Shares Drop
Trendline Trendline
Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint
Trendline Trendline
Moderna Maintains Growth Target Despite Norovirus Vaccine Setback

Moderna Maintains Growth Target Despite Norovirus Vaccine Setback

Moderna Maintains Growth Target Despite Norovirus Vaccine Setback
Rapid Read Rapid Read
New Model Proposes Dimensional Approach to Neurodevelopment in CHD

New Model Proposes Dimensional Approach to Neurodevelopment in CHD

A recent article in Frontiers in Pediatrics proposes a new dimensional model to understand neurodevelopmental outcomes in children with congenital heart disease (CHD). The model suggests that outcomes are influenced by both biological vulnerabilities and environmental adversities, categorized into deprivation and threat. This approach aims to provide a more mechanistic understanding of how specific experiences impact neurodevelopment, moving beyond traditional models that focus on cataloging risk factors without explaining their effects. The model integrates various factors, including prenatal conditions, perioperative brain injury, and socioeconomic influences, to predict developmental trajectories more accurately.
Trendline Trendline
Orano Med Reports Progress in Nuclear Medicine and Business Outlook

Orano Med Reports Progress in Nuclear Medicine and Business Outlook

Orano Med Reports Progress in Nuclear Medicine and Business Outlook
Rapid Read Rapid Read
University of Rochester's CTSI Secures $29 Million for Translational Science

University of Rochester's CTSI Secures $29 Million for Translational Science

The University of Rochester Medicine Clinical & Translational Science Institute (CTSI) has received over $29 million in federal funding from the National Institutes of Health. This funding is part of the Clinical and Translational Science Awards Program, aimed at advancing translational science and clinical trials. CTSI has been pivotal in supporting research that moves discoveries from the lab to clinical applications, focusing on improving health outcomes. The funding will enhance research capabilities, support training and mentorship, and strengthen community engagement, particularly with rural areas. The institute has been a leader in translational research since its inception in 2006.
Rapid Read Rapid Read
New Drugs Show Promise in Preventing Long COVID, Offering Hope for Millions

New Drugs Show Promise in Preventing Long COVID, Offering Hope for Millions

Recent clinical trials have shown that a diabetes drug and an antiviral medication used for mild-to-moderate COVID-19 can potentially prevent the development of long COVID. Long COVID is characterized by symptoms such as fatigue, shortness of breath, and cognitive impairment that persist for more than three months after initial infection. The trials, which included a placebo-controlled study, revealed that the antiviral Paxlovid reduced the risk of long COVID by 40% among participants. Additionally, a separate trial indicated that the diabetes drug metformin could cut the risk of physician-diagnosed long COVID by half. Despite these promising results, some physicians remain skeptical, citing concerns about the study's definitions and the self-reported nature of symptoms.